S&P 500   3,956.31 (-0.18%)
DOW   33,663.43 (-0.35%)
QQQ   284.08 (+0.08%)
AAPL   143.98 (+0.93%)
MSFT   246.96 (-0.18%)
META   116.64 (+1.14%)
GOOGL   93.48 (-0.25%)
AMZN   89.56 (-0.87%)
TSLA   180.68 (+4.17%)
NVDA   172.93 (+0.72%)
NIO   12.75 (-4.92%)
BABA   91.63 (-2.70%)
AMD   69.49 (-1.39%)
T   19.20 (+0.42%)
MU   55.51 (+0.56%)
CGC   2.91 (-5.83%)
F   13.23 (+0.84%)
GE   82.13 (-1.79%)
DIS   94.02 (+1.59%)
AMC   5.90 (-2.80%)
PYPL   73.90 (-0.43%)
PFE   51.91 (+0.25%)
NFLX   323.52 (+4.27%)
S&P 500   3,956.31 (-0.18%)
DOW   33,663.43 (-0.35%)
QQQ   284.08 (+0.08%)
AAPL   143.98 (+0.93%)
MSFT   246.96 (-0.18%)
META   116.64 (+1.14%)
GOOGL   93.48 (-0.25%)
AMZN   89.56 (-0.87%)
TSLA   180.68 (+4.17%)
NVDA   172.93 (+0.72%)
NIO   12.75 (-4.92%)
BABA   91.63 (-2.70%)
AMD   69.49 (-1.39%)
T   19.20 (+0.42%)
MU   55.51 (+0.56%)
CGC   2.91 (-5.83%)
F   13.23 (+0.84%)
GE   82.13 (-1.79%)
DIS   94.02 (+1.59%)
AMC   5.90 (-2.80%)
PYPL   73.90 (-0.43%)
PFE   51.91 (+0.25%)
NFLX   323.52 (+4.27%)
S&P 500   3,956.31 (-0.18%)
DOW   33,663.43 (-0.35%)
QQQ   284.08 (+0.08%)
AAPL   143.98 (+0.93%)
MSFT   246.96 (-0.18%)
META   116.64 (+1.14%)
GOOGL   93.48 (-0.25%)
AMZN   89.56 (-0.87%)
TSLA   180.68 (+4.17%)
NVDA   172.93 (+0.72%)
NIO   12.75 (-4.92%)
BABA   91.63 (-2.70%)
AMD   69.49 (-1.39%)
T   19.20 (+0.42%)
MU   55.51 (+0.56%)
CGC   2.91 (-5.83%)
F   13.23 (+0.84%)
GE   82.13 (-1.79%)
DIS   94.02 (+1.59%)
AMC   5.90 (-2.80%)
PYPL   73.90 (-0.43%)
PFE   51.91 (+0.25%)
NFLX   323.52 (+4.27%)
S&P 500   3,956.31 (-0.18%)
DOW   33,663.43 (-0.35%)
QQQ   284.08 (+0.08%)
AAPL   143.98 (+0.93%)
MSFT   246.96 (-0.18%)
META   116.64 (+1.14%)
GOOGL   93.48 (-0.25%)
AMZN   89.56 (-0.87%)
TSLA   180.68 (+4.17%)
NVDA   172.93 (+0.72%)
NIO   12.75 (-4.92%)
BABA   91.63 (-2.70%)
AMD   69.49 (-1.39%)
T   19.20 (+0.42%)
MU   55.51 (+0.56%)
CGC   2.91 (-5.83%)
F   13.23 (+0.84%)
GE   82.13 (-1.79%)
DIS   94.02 (+1.59%)
AMC   5.90 (-2.80%)
PYPL   73.90 (-0.43%)
PFE   51.91 (+0.25%)
NFLX   323.52 (+4.27%)
NASDAQ:CGTX

Cognition Therapeutics - CGTX Stock Forecast, Price & News

Notice: Trading of Cognition Therapeutics halted at 10:57 AM EST due to "LULD pause".
$2.81
-0.24 (-7.87%)
(As of 12/9/2022 02:20 PM ET)
Add
Compare
Today's Range
$2.65
▼
$3.08
50-Day Range
$1.17
▼
$3.51
52-Week Range
$1.07
▼
$8.83
Volume
2,807 shs
Average Volume
444,154 shs
Market Capitalization
$63.82 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.00

Cognition Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
362.6% Upside
$13.00 Price Target
Short Interest
Healthy
0.88% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$57,100 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.05) to ($1.41) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.99 out of 5 stars

Medical Sector

380th out of 1,022 stocks

Biological Products, Except Diagnostic Industry

62nd out of 171 stocks

See Top Rated MarketRank™ Stocks Here
CGTX stock logo

About Cognition Therapeutics (NASDAQ:CGTX) Stock

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.

Receive CGTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cognition Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CGTX Stock News Headlines

December 1, 2022 | finance.yahoo.com
Cognition Therapeutics Presents Scientific Rationale, Clinical Biomarker and Preclinical Data supporting a Phase 2 Clinical Trial with CT1812 in Geographic Atrophy Secondary to Dry AMD
December 1, 2022 | finance.yahoo.com
Cognition Therapeutics, Inc.'s (NASDAQ:CGTX) market cap surged US$46m last week, individual investors who have a lot riding on the company were rewarded
November 30, 2022 | americanbankingnews.com
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Director Ellen B. Richstone Purchases 10,000 Shares
November 28, 2022 | finance.yahoo.com
Cognition Therapeutics Highlights Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies in Presentation at CTAD
November 21, 2022 | 247wallst.com
Orin Hirschman Discloses Large Position in CGTX / Cognition Therapeutics
November 21, 2022 | finance.yahoo.com
Cognition Therapeutics Launches Neuroscience Thought Leader Conversations Podcast/Webinar Series
November 17, 2022 | benzinga.com
Cognition Therapeutics Board Member Makes $99K Stock Purchase
November 17, 2022 | benzinga.com
Board Member of Cognition Therapeutics Purchased $99K In Stock
November 16, 2022 | benzinga.com
Massive Insider Trade At Cognition Therapeutics
November 16, 2022 | finanznachrichten.de
Cognition Therapeutics, Inc.: Cognition Therapeutics Announces Closing of Public Offering
November 15, 2022 | finance.yahoo.com
Cognition Therapeutics Announces Closing of Public Offering
November 14, 2022 | finanznachrichten.de
Cognition Therapeutics, Inc.: Cognition Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
November 14, 2022 | benzinga.com
Cognition Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
November 14, 2022 | finance.yahoo.com
Cognition Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
November 10, 2022 | finance.yahoo.com
Cognition Therapeutics Announces Pricing of Public Offering
October 12, 2022 | finance.yahoo.com
Cognition Therapeutics is Recruiting for Lewy Body Dementia Phase 2 SHIMMER Trial in Seventeen Research Sites Across the U.S.
October 11, 2022 | finance.yahoo.com
Cognition Therapeutics Appoints CNS Drug Development Expert to VP Clinical Development
September 29, 2022 | finance.yahoo.com
Cognition Therapeutics to Participate in the 2022 Cantor Fitzgerald Neurology & Psychiatry Conference
September 27, 2022 | finance.yahoo.com
Cognition Therapeutics Awarded $2.14 Million in Supplemental Grant Funding from NIA to Support SEQUEL Clinical Trial
September 27, 2022 | finance.yahoo.com
Cognition Therapeutics Awarded $2.14 Million in Supplemental Grant Funding from NIA to Support SEQUEL Clinical Trial
September 6, 2022 | finance.yahoo.com
Cognition Therapeutics Announces Participation in September Investment Conferences
August 17, 2022 | bizjournals.com
Cognition Therapeutics sued by former CEO for $4M
August 11, 2022 | finance.yahoo.com
We Think Cognition Therapeutics (NASDAQ:CGTX) Can Afford To Drive Business Growth
August 9, 2022 | finance.yahoo.com
Cognition Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
August 9, 2022 | finance.yahoo.com
Cognition Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
See More Headlines
Receive CGTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cognition Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CGTX Company Calendar

Last Earnings
11/16/2021
Today
12/09/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/29/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CGTX
CUSIP
N/A
CIK
1455365
Web
www.cogrx.com
Phone
412-481-2210
Fax
N/A
Employees
19
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$13.00
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+362.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-11,720,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-51.42%
Return on Assets
-42.02%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.20
Quick Ratio
4.20

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.33 per share
Price / Book
1.21

Miscellaneous

Outstanding Shares
22,710,000
Free Float
18,044,000
Market Cap
$63.82 million
Optionable
Not Optionable
Beta
1.31

Key Executives

  • Ms. Lisa Ricciardi (Age 62)
    CEO, Pres & Director
    Comp: $677.2k
  • Dr. Anthony O. Caggiano M.D.
    Ph.D., Chief Medical Officer and Head of R&D
  • Mr. Andrew J. Einhorn CPA (Age 62)
    CFO, Principal Financial & Accounting Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













CGTX Stock - Frequently Asked Questions

Should I buy or sell Cognition Therapeutics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cognition Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CGTX shares.
View CGTX analyst ratings or view top-rated stocks.

What is Cognition Therapeutics' stock price forecast for 2023?

2 Wall Street research analysts have issued 1 year target prices for Cognition Therapeutics' stock. Their CGTX share price forecasts range from $9.00 to $20.00. On average, they anticipate the company's stock price to reach $13.00 in the next year. This suggests a possible upside of 326.2% from the stock's current price.
View analysts price targets for CGTX or view top-rated stocks among Wall Street analysts.

How have CGTX shares performed in 2022?

Cognition Therapeutics' stock was trading at $6.32 at the beginning of the year. Since then, CGTX shares have decreased by 51.7% and is now trading at $3.05.
View the best growth stocks for 2022 here.

Are investors shorting Cognition Therapeutics?

Cognition Therapeutics saw a increase in short interest in November. As of November 15th, there was short interest totaling 134,000 shares, an increase of 116.1% from the October 31st total of 62,000 shares. Based on an average daily volume of 119,900 shares, the days-to-cover ratio is currently 1.1 days. Approximately 0.9% of the shares of the stock are short sold.
View Cognition Therapeutics' Short Interest.

When is Cognition Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 29th 2023.
View our CGTX earnings forecast.

How were Cognition Therapeutics' earnings last quarter?

Cognition Therapeutics, Inc. (NASDAQ:CGTX) announced its earnings results on Tuesday, November, 16th. The company reported ($8.12) earnings per share for the quarter, missing the consensus estimate of ($0.57) by $7.55.

When did Cognition Therapeutics IPO?

(CGTX) raised $45 million in an IPO on Friday, October 8th 2021. The company issued 3,768,116 shares at $11.00-$13.00 per share.

What is Cognition Therapeutics' stock symbol?

Cognition Therapeutics trades on the NASDAQ under the ticker symbol "CGTX."

Who are Cognition Therapeutics' major shareholders?

Cognition Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (1.77%), Voss Capital LLC (0.96%), Worth Venture Partners LLC (0.88%), Carlson Capital L P (0.44%), P.A.W. Capital Corp (0.44%) and Rock Creek Group LP (0.22%). Insiders that own company stock include Ellen B Richstone, Lisa Ricciardi and Peggy Wallace.
View institutional ownership trends.

How do I buy shares of Cognition Therapeutics?

Shares of CGTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cognition Therapeutics' stock price today?

One share of CGTX stock can currently be purchased for approximately $3.05.

How much money does Cognition Therapeutics make?

Cognition Therapeutics (NASDAQ:CGTX) has a market capitalization of $69.27 million.

How can I contact Cognition Therapeutics?

The official website for the company is www.cogrx.com. The company can be reached via phone at 412-481-2210 or via email at news@cogrx.com.

This page (NASDAQ:CGTX) was last updated on 12/9/2022 by MarketBeat.com Staff